S1040-119

What This Bill Does

The Drug Competition Enhancement Act adds a product-hopping section to the Federal Trade Commission Act. It defines generic drugs, biosimilar biological products, listed drugs, reference products, follow-on products, manufacturers, and ultimate parent entities. A manufacturer of a listed drug or reference product commits an unfair method of competition if, after receiving notice of an ANDA or biosimilar application and during the statutory competition window, it uses a hard switch or soft switch that impedes generic or biosimilar competition while marketing or selling a follow-on product.

A hard switch includes asking FDA to withdraw approval or discontinue listing the old product and selling a follow-on product, or withdrawing, discontinuing, announcing discontinuance, or destroying inventory in a way that impedes competition. A soft switch covers other actions that unfairly disadvantage the old product relative to a follow-on product. The bill excludes truthful non-misleading promotion and ceasing promotion alone. Manufacturers can defend actions based on patient safety, supply disruptions outside their control, or legitimate procompetitive reasons. FTC can rebut those defenses, bring administrative proceedings, seek temporary or permanent injunctions, and pursue disgorgement or restitution within five years of unjust enrichment.

Who Benefits and How

Generic drug developers benefit because brand manufacturers face a defined FTC standard against hard-switch and soft-switch product hopping. Biosimilar developers benefit from the same protection when referencing biological products. Patients using affected drugs benefit if generic or biosimilar entry is not delayed by anticompetitive switching. Health plan payers benefit if competition lowers drug spending. FTC competition staff benefit from explicit enforcement authority and remedies.

Who Bears the Burden and How

Listed drug manufacturers face new antitrust exposure for withdrawing, discontinuing, destroying inventory, or disadvantaging older products to shift the market. Reference product manufacturers face the same risk for biologics. Pharmaceutical marketing teams must distinguish truthful promotion from anticompetitive switch strategy. FTC litigators must prove the statutory elements and rebut defenses. Federal courts must adjudicate injunction, disgorgement, restitution, and review petitions.

Key Provisions

• Defines pharmaceutical product hopping in the FTC Act.
• Prohibits hard switches involving withdrawal, discontinuance, inventory destruction, or discontinued-product listing used to impede competition.
• Prohibits soft switches that unfairly disadvantage an older product while marketing a follow-on product.
• Provides defenses for safety risks, supply disruptions, and legitimate procompetitive reasons.
• Authorizes FTC administrative proceedings, injunctions, disgorgement, restitution, and appellate review.